The economic burden associated with prior authorizations in an allergist office

Allergy and Asthma Proceedings

Volumn 27, Issue 2, 2006, Pages 119-122

  Bukstein, Don A ^a   Cherayil, Greeta A ^b   Gepner, Adam D ^a   Luskin, Allan T ^a   Kooistra, J Brent ^a   Olson, Reid M ^a  

^a DEAN MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST; DRUG COST; ECONOMICS; HEALTH INSURANCE; HUMAN; IMMUNOLOGY; INSURANCE; PRESCRIPTION; PUBLICATION; TIME; WORKLOAD;

ALLERGY AND IMMUNOLOGY; COSTS AND COST ANALYSIS; DRUG COSTS; FORMULARIES; HUMANS; INSURANCE COVERAGE; INSURANCE, PHARMACEUTICAL SERVICES; MANAGED CARE PROGRAMS; PRESCRIPTIONS, DRUG; TIME FACTORS; WORKLOAD;

EID: 33646469627     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Burton SL, Randel L, Titlow K, and Emanuel EJ. The ethics of pharmaceutical benefit management. Health Aff 20:150-164, 2001.
2. Scherer FM. The pharmaceutical industry-prices and progress. N Engl J Med 351:927-932, 2004.
3. Baugh DK, Pine PL, Blackwell S, et al. Medicaid prescription drug spending in the 1990s: A decade of change. Heath Care Financ Rev 25:5-23, 2004.
4. Smalley WE, Griffin MR, Fought RL, et al. Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs by Medicaid patients. N Engl J Med 332: 1612-1617, 1995.
5. Kotzan JA, et al. Initial impact of a Medicaid Maintenance Dose Program for H2 antagonist prescriptions. J Res Pharm Econ 5:43-58, 1993.
6. Fischer MA, Schneeweiss S, Avorn J, et al. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med 351:2187-2194, 2004.
7. U.S. General Accounting Office (GAO). Prescription Drugs: FDA Oversight of Direct-to-Consumer Advertising Has Limitations. Publication No. GAO-03-177, Washington, D.C.: GAO, October 2002.
8. Hamel MB, and Epstein AM. Prior-authorization programs for controlling drug spending. N Engl J Med 351:2156-2158, 2004.
9. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff 23:135-146, 2004.
10. Fleming H Jr. Surprise! Closed formularies actually boost health costs. Drug Topics 144:90, 2000.
11. Big HMO to give decisions on care back to doctors. NY Times 9:A1, 1999.
12. Soumerai SB, Ross-Degnan D, Avorn J, et al. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med 325:1072-1077, 1991.
13. Fortess EE, et al. Utilization of essential medications by vulnerable elderly after a drug benefit cap: Importance of mental disorders, chronic pain, and practice setting. J Am Geriatr Soc 49:793-797, 2001.
14. American Medical Association Code of Medical Ethics. Financial incentives to limit car. H-140.978(2).
15. Cohen LJ. Looking beyond the formulary budget in cost-benefit analysis. Am J Manag Care 3(suppl):S11-S17, 1997.
16. Wilson A. De-mystifying pharmacoeconomics. Drug Benefit Trends 11:56-67, 1999.